Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This is the first investigational therapy in a Phase III trial to improve overall survival in uveal melanoma,” a cancer of the eye.
Kimmtrak, the first approved bispecific T-cell engager, improved overall survival in a clinical trial.
There’s no FDA-approved treatment for uveal, or eye, melanoma, but a new immunotherapy and molecular therapy show encouraging results.
Retinoblastoma is an uncommon cancer of the eye that is curable when diagnosed in its early stages.
Uveal melanoma occurs when melanin-producing cells form tumors in the eye, and is very different from cutaneous (skin) melanoma.
Doctors are perplexed by the dozens of cases of ocular melanoma in North Carolina and Alabama.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.